218 related articles for article (PubMed ID: 30478785)
21. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
22. GPER-1/GPR30 a novel estrogen receptor sited in the cell membrane: therapeutic coupling to breast cancer.
Molina L; Figueroa CD; Bhoola KD; Ehrenfeld P
Expert Opin Ther Targets; 2017 Aug; 21(8):755-766. PubMed ID: 28671018
[TBL] [Abstract][Full Text] [Related]
23. Opposite effects of tamoxifen on metabolic syndrome-induced bladder and prostate alterations: a role for GPR30/GPER?
Comeglio P; Morelli A; Cellai I; Vignozzi L; Sarchielli E; Filippi S; Maneschi E; Corcetto F; Corno C; Gacci M; Vannelli GB; Maggi M
Prostate; 2014 Jan; 74(1):10-28. PubMed ID: 24037776
[TBL] [Abstract][Full Text] [Related]
24. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of G Protein-Coupled Estrogen Receptor (GPER) is Associated with Reduced Prognosis in Patients with Gastric Cancer.
Tian S; Zhan N; Li R; Dong W
Med Sci Monit; 2019 Apr; 25():3115-3126. PubMed ID: 31028714
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.
Detre SI; Ashley S; Mohammed K; Smith IE; Powles TJ; Dowsett M
Cancer Prev Res (Phila); 2017 Mar; 10(3):171-176. PubMed ID: 28100469
[TBL] [Abstract][Full Text] [Related]
27. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
Liu S; Chia SK; Mehl E; Leung S; Rajput A; Cheang MC; Nielsen TO
Breast Cancer Res Treat; 2010 Jan; 119(1):53-61. PubMed ID: 19205877
[TBL] [Abstract][Full Text] [Related]
28. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.
Ahn SH; Son BH; Kim SW; Kim SI; Jeong J; Ko SS; Han W;
J Clin Oncol; 2007 Jun; 25(17):2360-8. PubMed ID: 17515570
[TBL] [Abstract][Full Text] [Related]
29. HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women.
Wege AK; Chittka D; Buchholz S; Klinkhammer-Schalke M; Diermeier-Daucher S; Zeman F; Ortmann O; Brockhoff G
Breast Cancer Res; 2018 Nov; 20(1):139. PubMed ID: 30458882
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
[TBL] [Abstract][Full Text] [Related]
31. Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort.
Elebro K; Borgquist S; Simonsson M; Markkula A; Jirström K; Ingvar C; Rose C; Jernström H
Clin Cancer Res; 2015 Aug; 21(16):3640-50. PubMed ID: 25904752
[TBL] [Abstract][Full Text] [Related]
32. GPER-1 expression decreases during breast cancer tumorigenesis.
Ignatov T; Weißenborn C; Poehlmann A; Lemke A; Semczuk A; Roessner A; Costa SD; Kalinski T; Ignatov A
Cancer Invest; 2013 Jun; 31(5):309-15. PubMed ID: 23688258
[TBL] [Abstract][Full Text] [Related]
33. Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy.
Morgan DA; Refalo NA; Cheung KL
Breast; 2011 Jun; 20(3):215-9. PubMed ID: 21159509
[TBL] [Abstract][Full Text] [Related]
34. PAX2 expression is correlated with better survival in tamoxifen-treated breast carcinoma patients.
Jahangiri R; Mosaffa F; Gharib M; Emami Razavi AN; Abdirad A; Jamialahmadi K
Tissue Cell; 2018 Jun; 52():135-142. PubMed ID: 29857823
[TBL] [Abstract][Full Text] [Related]
35. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
[TBL] [Abstract][Full Text] [Related]
36. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer.
Love RR; Duc NB; Havighurst TC; Mohsin SK; Zhang Q; DeMets DL; Allred DC
J Clin Oncol; 2003 Feb; 21(3):453-7. PubMed ID: 12560434
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer.
Iwase H; Zhang Z; Omoto Y; Sugiura H; Yamashita H; Toyama T; Iwata H; Kobayashi S
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S34-8. PubMed ID: 12819932
[TBL] [Abstract][Full Text] [Related]
38. Low SAFB levels are associated with worse outcome in breast cancer patients.
Hammerich-Hille S; Bardout VJ; Hilsenbeck SG; Osborne CK; Oesterreich S
Breast Cancer Res Treat; 2010 Jun; 121(2):503-9. PubMed ID: 19137425
[TBL] [Abstract][Full Text] [Related]
39. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
40. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
Gruvberger-Saal SK; Bendahl PO; Saal LH; Laakso M; Hegardt C; Edén P; Peterson C; Malmström P; Isola J; Borg A; Fernö M
Clin Cancer Res; 2007 Apr; 13(7):1987-94. PubMed ID: 17404078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
